A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Trial Details
- NCT ID
- NCT05838521
- Phase
- PHASE2
- Sponsor
- Yale University
- Status
- RECRUITING
- Cancer Type
- Cervical Cancer
- Interventions
- Locations (sample)
- New Haven, Connecticut, United States|41.30815,-72.92816
- Cleveland, Ohio, United States|41.4995,-81.69541
Key Eligibility Criteria
- Patients must have radiologically confirmed (i.e., CAT scan and/or MRI) persistent or recurrent histologically confirmed cervical cancer of epithel…
- Must have availability of archival tumor tissue FFPE block for TROP-2 testing
- Chemotherapy administered concurrent with primary radiation (i.e., weekly cisplatin) is not counted as a systemic chemotherapeutic regimen for mana…
- All patients must have measurable disease.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Cervical Cancer Trials on Trialify →